|
GM. This is The Financial Darwin Awards, the only financial newsletter with a 100% loss rate. Tuesday was about size. Not one of these four had a stupid idea. Gold is a war hedge, the lupus drug is a real drug, Axon is a real business, and GoPro genuinely was dying. Every one of them was taken apart by how much they had on. Four traders lost $103,345 between them, and all four could have held exactly the same view in a smaller size and still had an account this morning. The traders are composites. The moves are not. Here's what we've got today:
THIS WEEK'S DAMAGE REPORT 📊
The first number is the sum of the four stories below. The second is real: Axon closed Tuesday at $518.30, down 8.52%, and even after that fall it still trades at roughly 215 times earnings.
DARWIN AWARD OF THE WEEK 🏆 Every issue we crown the single worst financial decision on the internet. This week it goes to a man whose position was losing money, so he bought a second one exactly like it. Here's the setup. u/the_hedge_just_needs_time owned 1,500 shares of GLD, the gold ETF, as insurance against precisely the sort of week this was turning into. The insurance was not paying. Gold had drifted lower through the end of August while the Middle East got worse rather than better. Monday itself was an Iran session, with American strikes on Iranian rocket launchers and Iranian retaliation against bases in Jordan, and gold still did not go up. On Monday evening he doubled the position to 3,000 shares, about $1.22 million of gold, on the reasoning that the hedge was early rather than wrong. On Tuesday the United States struck Iran again. WTI settled at $90.22, up 5.20%, and Brent finished at $94.65. Gold fell 2.86%. GLD closed at $396.75, down $11.67 from Monday. 3,000 shares, down $11.67 each, is $35,010 in one session. Half of that loss did not exist on Monday morning. He created it on Monday evening. The hedge failing was bad luck. Doubling it was a decision, and the decision is the part that cost $35,010.
Here's the thing. Adding to a losing position is the cleanest way to turn a small mistake into one you cannot come back from. It feels like conviction and it behaves like leverage. The arithmetic is unkind. Averaging down improves your average price and worsens your worst case, and only one of those two can end you. There is also a reason gold kept falling while the shooting got louder. Gold pays no interest, so it competes with cash, and an oil shock is inflationary. The 10-year Treasury yield closed Tuesday at 4.796%, and higher yields make a metal that yields nothing worth less. That is the part worth understanding, and it cost him $35,010 to learn that the size of a hedge has to be settled before you need it, not after it disappoints you.
THIS WEEK'S CASUALTIES 💀 Not everybody can be Darwin Award of the week. These three gave it a real shot. Let's run through the tape. Casualty #1: The Man Who Owned One Readout u/subgroup_analysis_enjoyer held 2,200 shares of Alumis, about $48,000 at Monday's close of $21.81. That was roughly a third of his account, in a clinical-stage biotech, going into a Phase 2b readout. The trial was LUMUS: 408 patients over 48 weeks, testing an oral TYK2 inhibitor called envudeucitinib in moderate to severe systemic lupus. On Tuesday morning Alumis reported that the trial missed its primary and secondary endpoints in the overall population. There was a real signal in a prespecified subgroup with a high interferon gene signature, and the company said those patients were unexpectedly under-represented in the trial. The chief medical officer called the effect in that subgroup "highly compelling," and the company intends to talk to regulators about Phase 3. Alumis closed at $9.47, down $12.34, or 56.58%. 2,200 shares, down $12.34 each, is $27,148. The drug may well have a future. A third of an account does not get a second readout.
Casualty #2: The Man Who Bought Quality At Any Price u/great_company_any_price owned 450 shares of Axon Enterprise, about $255,000 at Monday's close of $566.56. This was not a speculation. Axon sells Tasers, body cameras and the software American police departments run on, and it is a genuinely good business. Revenue grew about 35% year on year to roughly $904 million in the quarter it reported on August 5. On Tuesday it fell 8.52% to $518.30, and there was no company news at all. No guidance change, no downgrade, no product problem. What moved was the discount rate. The 10-year Treasury yield closed at 4.796% as oil surged, and long yields kept climbing with it. At roughly 215 times earnings, nearly all of Axon's share price is cash flow that has not happened yet, and a higher yield makes distant cash flow worth less today. 450 shares, down $48.26 each, is $21,717. He thought he owned a police technology company. On Tuesday he found out he owned a very long-dated bond with a body camera attached.
Casualty #3: The Man Who Was Right Until Breakfast u/it_was_going_to_zero_anyway was short 55,000 shares of GoPro, about $48,200 of stock at Monday's close of roughly 88 cents. The short had been right for a long time and there was very little left of it to be right about, because a stock at 88 cents can only fall 88 more. On Tuesday morning GoPro announced a definitive agreement to merge with Starman Optical, a private American optical-photonics company, in a $285 million recapitalisation. Shareholders are to receive $1.14 a share in cash and keep about 10% of the recapitalised company, which stays listed on Nasdaq and moves into optical transceivers for data centres and defence. About $92 million of GoPro's obligations are to be repaid in full at closing. GoPro closed at $1.23, up 40.38%, after trading above $1.60 during the session on 491 million shares. 55,000 shares, up 35.4 cents each against him, is $19,470. At the session high the position was down more than $40,000. The camera business really was finished. The listing, the optics team and a balance sheet worth cleaning up were not.
THIS WEEK BY THE NUMBERS 📊 We track the data because the data is funnier than anything we could make up.
Every one of Tuesday's four had a defensible view of the world. What none of them had was a position small enough to survive being early, unlucky, repriced or outbid.
BITE-SIZED COPIUM FOR THE ROAD 🍪 The best part of any loss thread isn't the screenshot. It's the comments section. Here are this week's greatest hits.
Translation: everybody held a reasonable opinion in an unreasonable quantity.
DUMB MEMES 🤣 Every newsletter needs a meme section. Ours just hits different when the idea was fine and the number of them was not.
POV: the subgroup was significant
u/the_hedge_just_needs_time, on Monday evening If you laughed, you're coping. If you didn't laugh, go and work out what percentage of your account is in your favourite idea. See you next issue. Same convictions. Smaller, we hope. Traders and P&L screenshots are satirical composites. Market data, price moves and quotations are real and dated August 31 to September 1, 2026. Not financial advice. Obviously. Look at us. Stay liquid, |
Nobody picked the wrong side on Tuesday. They picked the wrong size
A gold hedge doubled at the worst possible moment, a third of an account on one lupus readout, 215 times earnings meeting a rising yield, and a short in a dying company that got bought for cash.
